Clinical Scorecard: Genetic Analysis of Complement Factors in Japanese Pediatric Patients with Transplant-Associated Thrombotic Microangiopathy

At a Glance

Key Highlights

• TA-TMA is a serious complication of hematopoietic stem cell transplantation.
• No significant difference in genetic variants between patients with and without TA-TMA was found.
• A novel rare variant in the C1r-like protein (C1RL) gene was identified in one patient.
• Complement dysregulation is a key pathway in TA-TMA pathogenesis.
• Eculizumab is considered effective in selected cases of TA-TMA.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of TA-TMA should be based on established criteria such as the Cho criteria or modified Jodele criteria.

Management

• Therapeutic complement inhibition with eculizumab may be effective in cases with evidence of complement activation.

Monitoring & Follow-up

• Patients should be monitored for signs of endothelial injury and complement activation.

Risks

• TA-TMA can progress to life-threatening disease, with an incidence of 30%-35% in HSCT recipients.

Patient & Prescribing Data

Japanese pediatric patients who underwent HSCT

Further studies with larger cohorts are necessary to clarify genetic associations.

Clinical Best Practices

• Conduct genetic analysis of complement-related genes in patients with suspected TA-TMA.
• Utilize established diagnostic criteria for accurate identification of TA-TMA.

Related Resources & Content

• Jodele et al. (2016)
• European Group for Blood and Marrow Transplantation
• Blood and Marrow Transplant Clinical Trial Network